The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

  title={The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.},
  author={Dick de Zeeuw and Blai Coll and Dennis L. Andress and John J. Brennan and Hui Bin Tang and Mark T. Houser and Ricardo Correa-Rotter and Donald E Kohan and Hiddo Jan Lambers Heerspink and Hirofumi Makino and Vlado Perkovic and Yili Lu Pritchett and Giuseppe Remuzzi and Sheldon W Tobe and Robert Daniel Toto and Giancarlo C Viberti and Henrik Parving},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={25 5},
Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria. We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduces albuminuria when administered concomitantly with maximum tolerated labeled doses of RAS inhibitors. We enrolled 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 25 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 53 extracted citations

Endothelin Blockade in Diabetic Kidney Disease

Journal of clinical medicine • 2015
View 3 Excerpts
Highly Influenced

Diabetic nephropathy: newer therapeutic perspectives

Journal of community hospital internal medicine perspectives • 2018
View 1 Excerpt

C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…